| NCT ID | NCT05738005 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Barbara Ann Karmanos Cancer Institute |
| Condition | Amyloidosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-03-02 |
| Primary Completion | 2025-11-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-03-02 with a primary completion date of 2025-11-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn about malnutrition and weight loss in patients with Amyloidosis. The main question it aims to answer is: Is it feasible to use a low-cost nutrition-based application (apps) for use on a smartphone to obtain detailed information on caloric intake in Amyloidosis patients Participants will be asked to: * Download the MyFitnessPal application on their smartphone and view an online tutorial * After a week of practice, from weeks 2-9, participants will enter daily dietary intake as well as daily herbal/alternative supplement intake into the MyFitnessPal application on their smartphone. * complete a questionnaire prior to starting the application, after week 2 and at week 10 after starting the application
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Diagnosed with any type of amyloidosis * Speak, read and write in English * Willing to use the MyFitnessPal app on their own smartphone Exclusion Criteria: * a planned autologous stem cell transplant or a solid organ transplant in the 12 weeks after enrollment * cognitive or perceptual disturbances
Contact & Investigator
Jeffrey Zonder, MD
PRINCIPAL INVESTIGATOR
Barbara Ann Karmanos Cancer Institute
Frequently Asked Questions
Who can join the NCT05738005 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05738005 currently recruiting?
Yes, NCT05738005 is actively recruiting participants. Contact the research team at zonderj@karmanos.org for enrollment information.
Where is the NCT05738005 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT05738005 clinical trial?
NCT05738005 is sponsored by Barbara Ann Karmanos Cancer Institute. The principal investigator is Jeffrey Zonder, MD at Barbara Ann Karmanos Cancer Institute. The trial plans to enroll 40 participants.